Reunion Neuroscience Inc.
REUN.TO
Toronto Stock Exchange1.42
CAD
-0.04
- -
Reunion Neuroscience Inc.
REUN.TO
(Toronto Stock Exchange)
Recent
price
1.42
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Reunion Neuroscience Inc. operates as a clinical-stage biopharmaceutical company, striving to redefine treatment approaches for mental health conditions that are currently underserved. The company is actively engaged in developing advanced psychedelic-inspired therapeutic solutions, with a strong focus on its lead compound, RE104. This proprietary asset is being clinically investigated for its potential in treating postpartum depression, generalized anxiety disorder, and adjustment disorder in various medical contexts. Reunion Neuroscience designs its candidates, such as RE104, to offer a brief, controlled psychoactive experience, distinguishing them from longer-duration psychedelics. The firm is also advancing RE245, a non-psychedelic compound, through its discovery pipeline. Originating as a spin-out from Field Trip Health in 2022, Reunion Neuroscience Inc. secured significant Series A funding in 2025, following its acquisition by MPM BioImpact in 2023, and is now headquartered in Morristown, New Jersey.